Cullinan Therapeutics (CGEM) · velinotamig
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: Q4 2026
Additional multi-dose regimen data from the study are expected to be shared in Q4 2026.
EX-99.1 · filed · SEC filing
After
Stated timing: November
in a poster session at American College of Rheumatology Convergence 2026 in November.
SEC original · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/CGEM-velinotamig-2026-09-24, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/CGEM-velinotamig-2026-09-24
Cullinan Therapeutics (CGEM) pipeline and stated timing · Calendar · Companies A–Z